Switch to DTG+3TC in a Highly Treatment-Experienced Person Living with HIV
Makaleler > Tam Makale · 2022
Yazarlar: Ayşe Deniz GÖKENGİN, Oğuzhan Acet
Mediterranean Journal of Infection Microbes and Antimicrobials, Uluslararası, Scopus, 2022
DOI: 10.4274/mjima.galenos.2022.2022.46
Özet
Dolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression.Although clinical studies and real-life data suggest that virologic suppression could be achieved or maintained in patients with baseline or acquired M184V/I mutation, doubts exists about its use.This report presents a patient living with human immunodeficiency virus infection who had no resistance test results available, had heavy treatment experience, and maintained viral suppression following switching to DTG + 3TC dual therapy.